Krystal Biotech Reports Third Quarter 2020 Financial Results and Provides Update on Operational Progress
- Pivotal GEM-3 study of B-VEC in DEB expected to complete enrollment in early 2021
- Initiated the Phase 1 Study of KB301 in Facial Wrinkles and Acne Scars
- Today announced additional in vivo preclinical data supporting the development of KB407 in cystic fibrosis
- Strong balance sheet with cash, cash equivalents and short-term investments of
“Despite the challenges presented by COVID in this quarter, we initiated a pivotal trial for DEB, a phase 2 trial in ARCI and a phase 1 trial in aesthetic skin conditions, and I thank my entire team for their efforts in these difficult times,” said
He further noted, “With the granting of Rare Pediatric Designation for this program by the FDA this quarter, we are now eligible to receive a Priority Review Voucher for KB407 as well as for B-VEC, KB105, KB104.”
Program Highlights & Upcoming Events
Beremagene Geperpavec (B-VEC) for DEB
- Enrollment in the ongoing pivotal GEM-3 study is proceeding well and enrollment completion is anticipated in early 2021. The trial is a randomized, double-blind, intra patient placebo-controlled multicenter trial designed to evaluate the efficacy and safety of B-VEC for patients suffering from both recessive and dominant dystrophic forms of Epidermolysis Bullosa.
- Details of the pivotal study can be found at www.clinicaltrials.gov under NCT identifier NCT04491604.
- Top line data and BLA filing are anticipated in 2021, in line with prior guidance. Data from this trial will also form the basis of an MAA filing in the EU which is anticipated to occur shortly after the BLA filing.
KB105 for TGM1-ARCI
September 2020, preclinical data supporting the development of KB105 in TGM1-related Autosomal Recessive Congenital Ichthyosis (ARCI) were published online ahead of print in the peer-reviewed Journal of Investigative Dermatology.
- Dosing of the 4th patient in the Phase 1/2 study of KB105 in patients with TGM1 deficient autosomal recessive congenital ichthyosis (ARCI) has completed. Treatment of a larger area and therefore higher dose is being evaluated. Data from this patient together with the data from the 3 initial patients, will help determine next steps.
- Details of the Phase 2 study can be found at www.clinicaltrials.gov under NCT identifier NCT04047732.
- The Company plans to present an update on this program in the first half of 2021.
KB407 for Cystic Fibrosis
- New in vivo data from the ongoing preclinical development of KB407 shows successful nebulization, distribution of vector and functional protein expression throughout the lung in mice and a nonhuman primate. More detailed results are available in a corporate presentation available under the Investors section of our website, here.
September 2020, KB407 was granted Rare Pediatric Designation by the FDA.
During the third quarter of 2020, we received a Notice of Allowance for our patent application covering methods of using KB407 for the treatment of Cystic fibrosis and other diseases causing progressive lung destruction, which is expected to issue as US Pat. No. 10,829,529 on
November 10th, 2020. As previously announced, in August 2020, the FDA granted Orphan Drug Designation for KB407.
- Pre-clinical validation work is ongoing, and the Company is on track to initiate a clinical study in the first half of 2021.
KB301 for Aesthetic Indications
October 2020, positive preclinical data supporting the ongoing development of KB301 in aesthetic indications was presented at the American Society for Dermatologic Surgery(ASDS) 2020 Virtual Meeting.
During the third quarter of 2020, the United States Patent Office (USPTO) granted
U.S.Patent No. 10,786,438 which covers pharmaceutical compositions comprising HSV vectors encoding one or more cosmetic proteins, as well as methods of their use for improving skin condition, quality, and/or appearance.
The Phase 1 study of KB301 for the treatment of shallow to moderately deep facial wrinkles and severe atrophic acne scars initiated in
- Initial safety data from this study is anticipated in early 2021, followed by initial efficacy data in 2H21.
KB104 for Netherton Syndrome
- The Company continues to work towards an IND filing, which is anticipated in 2021.
Financial results for the quarter ended
Cash, cash equivalents and short-term investments totaled
$286.4 millionon September 30, 2020.
Research and development expenses for the third quarter ended
September 30, 2020were $5.1 million, compared to $3.9 millionfor third quarter 2019.
General and administrative expenses for the third quarter ended
September 30, 2020were $4.6 million, compared to $1.5 millionfor third quarter 2019.
Net losses for the quarters ended
September 30, 2020and 2019 were $9.6 millionand $4.3 million, or ( $0.49) and ( $0.25) respectively, per common share (basic and diluted).
For additional information on the Company’s financial results for the third quarter ended
September 30, 2020, refer to form 10-Q filed with the SEC.
Any statements in this press release about future expectations, plans and prospects for